SCHEMBL6432243

SCHEMBL6432243

CC(C)COCC(O)CN1CCN(CC(O)COCC(C)C)CCN(CC(O)COCC(C)C)CC1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.47
USP2 O75604 3/20 0.47
GAA P10253 1/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47
RAB9A P51151 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
KDM4E B2RXH2 3/20 0.46
TSHR P16473 2/20 0.46
GLA P06280 1/20 0.46
ALDH1A1 P00352 3/20 0.44
ALOX15 P16050 1/20 0.44
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
LMNA P02545 1/20 0.44
L3MBTL1 Q9Y468 3/20 0.43
MAPT P10636 1/20 0.41
ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20805381 0.93 SMN1; SMN2 (0.43) SMN1; SMN2USP2GAAMAPK1HTT
SCHEMBL25513926 0.93 KDM4E (0.57) SMN1; SMN2USP2GAAMAPK1HTT
SCHEMBL19605009 0.93 SMN1; SMN2 (0.43) SMN1; SMN2USP2GAAMAPK1HTT
SCHEMBL10655740 0.92 KMT2A (0.54) SMN1; SMN2GAAHTTKDM4ETSHR
SCHEMBL10471950 0.92 KMT2A (0.54) SMN1; SMN2GAAHTTKDM4ETSHR
SCHEMBL11770711 0.89 USP2 (0.55) SMN1; SMN2USP2GAAMAPK1HTT
SCHEMBL6429041 0.88 SMN1; SMN2 (0.43) SMN1; SMN2USP2GAAMAPK1HTT
SCHEMBL20812316 0.88 SMN1; SMN2 (0.40) SMN1; SMN2USP2GAAMAPK1HTT
SCHEMBL6429036 0.88 SMN1; SMN2 (0.43) SMN1; SMN2USP2GAAMAPK1HTT
SCHEMBL19606439 0.77 KDM4E (0.43) SMN1; SMN2USP2GAAMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5874573-A Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy CONCAT, INC. (US) 1999-02-23 US claimed
EP-0955044-B1 Method of inhibiting bacterial or fungal growth using a complexing agent CHELATOR LLC (US) 2005-11-16 EP disclosed
EP-1382332-A1 Method for inhibiting bacterial or fungal growth using a polyamine derivative as complexing agent Chelator LLC (US) 2004-01-21 EP disclosed
US-6469162-B1 SUCH COMPOUNDS INHIBIT MAMMALIAN, BACTERIAL, AND FUNGAL CELL REPLICATION AND ARE USEFUL IN THE TREATMENT OF NEOPLASIA, INFECTION, INFLAMMATION, IMMUNE REPONSE, AND IN TERMINATION OF PREGNANCY CONCAT, LTD. 2002-10-22 US disclosed
US-6165996-A Compounds with chelation affinity selectivity for first transition series elements: use in medical therapy and diagnosis CONCAT, INC. (US) 2000-12-26 US disclosed
EP-0955044-A2 Method of inhibiting bacterial or fungal growth using a complexing agent CONCAT LTD. (US) 1999-11-10 EP disclosed
US-5874573-A Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy CONCAT, INC. (US) 1999-02-23 US disclosed
EP-0841951-A2 COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS, AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS CONCAT LTD. (US) 1998-05-20 EP disclosed
WO-1997001360-A9 COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS 1997-07-17 WO disclosed
WO-1997001360-A2 COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS CONCAT, LTD. (US) 1997-01-16 WO disclosed